دورية أكاديمية
Cost-effectiveness of hydroxychloroquine versus placebo for hand osteoarthritis: economic evaluation of the HERO trial [version 1; peer review: 2 approved]
| العنوان: | Cost-effectiveness of hydroxychloroquine versus placebo for hand osteoarthritis: economic evaluation of the HERO trial [version 1; peer review: 2 approved] |
|---|---|
| المؤلفون: | Catherine Arundel, David J Torgerson, Sarah J Ronaldson, Ada Keding, Puvan Tharmanathan, Sarah R Kingsbury, Philip G Conaghan |
| المصدر: | F1000Research, Vol 10 (2021) |
| بيانات النشر: | F1000 Research Ltd, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Medicine LCC:Science |
| مصطلحات موضوعية: | economic evaluation, hand osteoarthritis, hydroxychloroquine, randomised controlled trial, cost-effectiveness analysis, cost-utility analysis, eng, Medicine, Science |
| الوصف: | Background: An economic evaluation alongside the Hydroxychloroquine Effectiveness in Reducing symptoms of hand Osteoarthritis (HERO) trial was undertaken to assess the cost-effectiveness of hydroxychloroquine compared with placebo for symptomatic treatment of hand osteoarthritis for patients with at least moderate hand pain and inadequate response to current therapies. Methods: A trial-based cost–utility analysis was undertaken from the perspective of the UK National Health Service and Personal Social Services over a 12-month time horizon, using evidence from 248 participants included in the HERO trial, conducted in England. Patient-level data were collected prospectively over a 12-month period, using participant-completed questionnaires and investigator forms, to collect healthcare utilisation, costs and quality-adjusted life years (QALYs) using the EQ-5D-5L. The base-case analysis was conducted on an intention-to-treat basis and used multiple imputation methods to deal with missing data. Results were presented in terms of incremental cost-effectiveness ratios (incremental cost per QALY) and net health benefit, with uncertainty surrounding the findings explored using cost-effectiveness acceptability curves. Results: The base-case analysis estimated slightly lower costs on average (−£11.80; 95% confidence interval (CI) −£15.60 to −£8.00) and marginally fewer QALYs (−0.0052; 95% CI −0.0057 to −0.0047) for participants in the hydroxychloroquine group versus placebo group at 12 months. The resulting incremental cost-effectiveness ratio of £2,267 per QALY lost indicated that although costs were saved, health-related quality of life was lost. Even assuming symmetrical preferences regarding losses and gains for health benefits, the findings do not fall within the cost-effective region. Similar findings arose for analyses conducted from the societal perspective and using complete cases only. Conclusions: This economic evaluation indicates that hydroxychloroquine is unlikely to provide a cost-effective pain relief option for improving health-related quality of life in adult patients with moderate-to-severe hand osteoarthritis. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2046-1402 |
| Relation: | https://f1000research.com/articles/10-821/v1; https://doaj.org/toc/2046-1402 |
| DOI: | 10.12688/f1000research.55296.1 |
| URL الوصول: | https://doaj.org/article/d6dbc24779ce44d294f9a522b3a2a7ea |
| رقم الأكسشن: | edsdoj.6dbc24779ce44d294f9a522b3a2a7ea |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20461402 |
|---|---|
| DOI: | 10.12688/f1000research.55296.1 |